Dr Robert (Bob) Anderson
1997 NHMRC / RG Menzies Fellow
Dr Anderson completed his NHMRC/RG Menzies post-doctoral fellowship at the University of Oxford in the Nuffield Department of Medicine, where he first started to focus on the immunology of coeliac disease and defining the disease-causing components of gluten. During the subsequent years his work has led to a detailed understanding of the immune response to gluten in patients with coeliac disease. The therapeutic vaccine for coeliac disease, Nexvax2®, now in clinical development led by ImmusanT, Inc. in the United States, arose directly from Dr Anderson’s research in Oxford and later at the Walter and Eliza Hall Institute in Melbourne.
Dr Anderson is an internationally recognised leader in coeliac disease. He initiated highly successful medical awareness programs to improve standards of care in coeliac disease in Australia, founding the Australia New Zealand Coeliac Research Fund and establishing dedicated clinics for coeliac disease in the Departments of Gastroenterology at The Royal Melbourne Hospital and Alfred Hospital.
Prior to relocating to the United States in 2012 as Chief Scientific Officer of biotech company ImmusanT, Dr Anderson was a Laboratory Head at the Walter and Eliza Hall Institute, and the gastroenterologist in charge of the Coeliac Disease Clinic at the Alfred Hospital in Melbourne.
Dr Anderson holds degrees in medicine and medical science, and a doctorate in experimental medicine in the field of innate immunity and digestive disease, all from the University of Otago in Dunedin, New Zealand.